Extended-Release Mirapex Approved for Parkinson's Disease

powered by healthline

Average Ratings

A once-daily treatment

WEDNESDAY, Feb. 24 (HealthDay News) -- Mirapex ER (pramipexole dihydrochloride extended-release) has been approved by the U.S. Food and Drug Administration as a once-daily option to treat early Parkinson's disease, drug maker Boehringer Ingelheim said in a news release.

Mirapex was first approved more than a decade ago. Approval of the extended-release form was based on a clinical study of more than 400 people with early Parkinson's who were assessed after nine weeks and 18 weeks.

The safety, tolerability and adverse effects of the extended-release form were similar to those of original Mirapex, the company said. The most frequently reported side effects included nausea, dizziness, sleepiness, insomnia, weakness and constipation.

Parkinson's is a chronic, progressive and often debilitating neurological disease affecting close to 1 million people in the United States, the drug maker said. One person is diagnosed with Parkinson's every nine minutes.

More information

The FDA has more information about this drug's approval history.

-- Scott Roberts
Copyright © 2010 HealthDay. All rights reserved.
Article from
Top of page
General Drug Tools
General Drug Tools view all tools
Tools for
Healthy Living
Tools for Healthy Living view all tools
Search Tools
Search Tools view all tools
Insurance Plan Tools
Insurance Plan Tools view all tools